참고문헌
- Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996;275:1571-6. https://doi.org/10.1001/jama.1996.03530440051036
- Thomas F, Bean K, Guize L, Quentzel S, Argyriadis P, Benetos A. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women. Eur Heart J 2002;23:528-35. https://doi.org/10.1053/euhj.2001.2888
- James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507-20. https://doi.org/10.1001/jama.2013.284427
- Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: Part II: AT(1) receptor regulation. Circulation 2002;105:530-6. https://doi.org/10.1161/hc0402.102619
- Keidar S, Kaplan M, Shapira C, Brook JG, Aviram M. Low density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages: a possible role for angiotensin II. Atherosclerosis 1994;107:71-84. https://doi.org/10.1016/0021-9150(94)90143-0
- Pool JL, Glazer R, Chiang YT, Gatlin M. Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. J Hum Hypertens 1999;13:275-81. https://doi.org/10.1038/sj.jhh.1000788
- Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906. https://doi.org/10.1056/NEJMoa032292
- Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31. https://doi.org/10.1016/S0140-6736(04)16451-9
- Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2889-934. https://doi.org/10.1016/j.jacc.2013.11.002
- White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002;42:963-70. https://doi.org/10.1177/0091270002042009002
- Borghi C, Prandin MG, Costa FV, Bacchelli S, Degli Esposti D, Ambrosioni E. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000;35:549-55. https://doi.org/10.1097/00005344-200004000-00006
- Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999;34:1281-6. https://doi.org/10.1161/01.HYP.34.6.1281
- Sposito AC, Mansur AP, Coelho OR, et al. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin- converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999;83:1497-9, A8. https://doi.org/10.1016/S0002-9149(99)00132-0
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97. https://doi.org/10.1001/jama.285.19.2486
- Cifkova R, Erdine S, Fagard R, et al. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 2003;21:1779-86. https://doi.org/10.1097/00004872-200310000-00001
- Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007;29:563-80. https://doi.org/10.1016/j.clinthera.2007.03.018
- Avis HJ, Hutten BA, Gagné C, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol 2010;55:1121-6. https://doi.org/10.1016/j.jacc.2009.10.042
- Wilson TW, Alonso-Galicia M, Roman RJ. Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension 1998;31:225-31. https://doi.org/10.1161/01.HYP.31.1.225
- Jiang J, Roman RJ. Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension 1997;30:968-74. https://doi.org/10.1161/01.HYP.30.4.968
- Nazzaro P, Manzari M, Merlo M, et al. Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension 1999;33:719-25. https://doi.org/10.1161/01.HYP.33.2.719
- Borghi C, Dormi A, D'Addato S, et al. Trends in blood pressure control and antihypertensive treatment in clinical practice: the Brisighella Heart Study. J Hypertens 2004;22;1707-16. https://doi.org/10.1097/00004872-200409000-00014
- Rajagopalan S, Zannad F, Radauceanu A, et al. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension. Am J Cardiol 2007;100:222-6. https://doi.org/10.1016/j.amjcard.2007.02.085
- O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126-31. https://doi.org/10.1161/01.CIR.95.5.1126
- Egede R, Jensen LO, Hansen HS, et al. Effect of intensive lipid-lowering treatment compared to moderate lipid-lowering treatment with rosuvastatin on endothelial function in high risk patients. Int J Cardiol 2012;158:376-9. https://doi.org/10.1016/j.ijcard.2011.01.071
- Lewis TV, Cooper BA, Dart AM, Chin-Dusting JP. Responses to endothelium- dependent agonists in subcutaneous arteries excised from hypercholesterolaemic men. Br J Pharmacol 1998;124:222-8. https://doi.org/10.1038/sj.bjp.0701800
- Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999;33:234-41. https://doi.org/10.1016/S0735-1097(98)00514-2
- Straznicky NE, Howes LG, Lam W, Louis WJ. Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension. Am J Cardiol 1995;75:582-6. https://doi.org/10.1016/S0002-9149(99)80621-3
- Savić V, Eržen B, Janić M, et al. Improvement of arterial wall characteristics by the low-dose fluvastatin and valsartan combination in type 1 diabetes mellitus patients. Diab Vasc Dis Res 2013;10:420-5. https://doi.org/10.1177/1479164113485102
- Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004;110:3687-92. https://doi.org/10.1161/01.CIR.0000143085.86697.13
- Roberts C, Torgerson DJ. Understanding controlled trials: baseline imbalance in randomized controlled trials. BMJ 1999;319:185.
피인용 문헌
- The combination of valsartan and ramipril protects against blood vessel injury and lowers blood pressure vol.46, pp.3, 2015, https://doi.org/10.1007/s40005-016-0241-4
- Blood pressure lowering effect of statin drugs with an application to rosuvastatin vol.24, pp.3, 2015, https://doi.org/10.12793/tcp.2016.24.3.132
- Blood Pressure and Cholesterol-lowering Efficacy of a Fixed-dose Combination With Irbesartan and Atorvastatin in Patients With Hypertension and Hypercholesterolemia: A Randomized, Double-blind, Factor vol.38, pp.10, 2015, https://doi.org/10.1016/j.clinthera.2016.09.005
- Statin Intensity and Clinical Outcome in Patients with Stable Coronary Artery Disease and Very Low LDL-Cholesterol vol.11, pp.11, 2016, https://doi.org/10.1371/journal.pone.0166246
- Fixed-dose combination therapy for cardiovascular prevention vol.59, pp.11, 2015, https://doi.org/10.5124/jkma.2016.59.11.883
- Antihypertensive effects of rosuvastatin in patients with hypertension and dyslipidemia: A systemic review and meta-analysis of randomized studies vol.16, pp.11, 2015, https://doi.org/10.1371/journal.pone.0260391
- Comparative efficacy of fixed-dose statin and antihypertensive agent combinations: A network meta-analysis of randomized controlled trials vol.141, pp.None, 2021, https://doi.org/10.1016/j.vph.2021.106900